인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
MRTX1133 is a first-in-class KRAS G12D inhibitor being in phase I/II clinical trials. KRAS is the most frequently mutated oncogene in pancreatic ductal adenocarcinoma (PDAC), with a predominance of the G12D variant. PDAC is a highly lethal cancer type with an extremely low 5-year survival rate. Although PDAC metastasis most frequently targets the liver, the influence of MRTX1133 treatment on hepatic metastases has not yet been investigated thoroughly. Thus, we aimed to analyze the effect of MRTX1133 treatment on local tumor growth and liver metastasis development. Cell proliferation and migration were investigated in vitro using clonogenic, scratch, Boyden chamber, and immunoblot assay in three KRAS G12D mutated PDAC cell lines (ASPC1, SW1990, PANC1). Moreover, PANC1 was examined in vivo in a spleen-to-liver metastatic xenograft model using NXG female mice. The MRTX1133 treatment decreased clonogenic proliferation and migratory activity; furthermore, it inhibited both local tumor growth in the spleen and liver colonization. MRTX1133 induced alterations associated with mesenchymal-to-epithelial transition; furthermore, lower levels of activated Erk, altered FAK expression, and activation were observed. In addition to the antiproliferative effects of MRTX1133, our in vitro and in vivo results indicate the importance of MRTX1133 as a potential antimetastatic drug in PDAC therapy.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
